Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial
Article in Cost Effectiveness and Resource Allocation (March 2023)
The most recent citing publications are shown below. View all 4 publications that cite this research output on Dimensions.
Role of FXR in Renal Physiology and Kidney Diseases
Article in International Journal of Molecular Sciences (January 2023)
Institutional and infrastructure challenges for hospitals producing advanced therapies in the UK: the concept of ‘point-of-care manufacturing readiness’
Article in Regenerative Medicine (September 2022)